Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $960.00 Price Target at TD Cowen

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target hoisted by TD Cowen from $880.00 to $960.00 in a research note published on Thursday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Other research analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. Bank of America upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their price target for the stock from $627.00 to $860.00 in a research note on Wednesday, January 7th. Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Royal Bank Of Canada raised their price target on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a “sector perform” rating in a research note on Monday, March 2nd. Finally, Evercore raised their price target on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $818.13.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $766.02 on Thursday. The firm’s 50-day moving average is $763.87 and its 200-day moving average is $729.93. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $821.11. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. The company has a market cap of $80.98 billion, a price-to-earnings ratio of 18.43, a PEG ratio of 1.66 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the previous year, the firm posted $12.07 EPS. The business’s revenue was up 2.5% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals will post 35.2 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.05%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. The trade was a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares in the company, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,774 shares of company stock worth $2,942,738 over the last ninety days. Corporate insiders own 7.02% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Insigneo Advisory Services LLC boosted its position in Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $343,000 after buying an additional 13 shares in the last quarter. Guardian Wealth Advisors LLC NC boosted its position in Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock valued at $342,000 after buying an additional 14 shares in the last quarter. TD Private Client Wealth LLC boosted its position in Regeneron Pharmaceuticals by 9.7% in the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 15 shares in the last quarter. MCF Advisors LLC boosted its position in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 15 shares in the last quarter. Finally, Rexford Capital Inc. boosted its position in Regeneron Pharmaceuticals by 5.5% in the fourth quarter. Rexford Capital Inc. now owns 288 shares of the biopharmaceutical company’s stock valued at $222,000 after buying an additional 15 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA approves Otarmeni, the first gene therapy to restore hearing — a clear pipeline win that validates Regeneron’s genetic?medicine platform and de?risks future revenue streams tied to novel products. Read More.
• Positive Sentiment: Regulatory and clinical data look strong — trial results cited high responder rates (e.g., CHORD trial outcomes reported), supporting commercial potential and positive sentiment around commercialization prospects. Read More.
• Positive Sentiment: Company secured tariff relief under the White House agreement (three years) — a near?term margin/cost benefit that investors view favorably. Read More.
• Positive Sentiment: Analyst support/upgrades — TD Cowen raised its price target (to $960) and Cantor Fitzgerald reaffirmed “overweight,” reinforcing buy-side conviction and likely contributing to demand. Read More.
• Positive Sentiment: Dupixent label expansions (U.S./EU pediatric approvals) add incremental, low?risk revenue upside and diversify near?term growth drivers beyond gene therapy. Read More.
• Neutral Sentiment: Regeneron will provide Otarmeni for free to eligible U.S. patients — a major PR/ access move that increases goodwill and access but reduces near?term product revenue in the U.S.; it may help uptake and market positioning internationally. Read More.
• Negative Sentiment: The agreement includes offering prescriptions at “most?favored?nation” prices for some Americans — this could compress pricing and long?run revenue/margins if broadly applied. Read More.
• Negative Sentiment: Sector weakness: broader health?care stocks were lower in afternoon trading, which can cap upside even with company?specific news. Read More.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.